Andrew Gengos - 07 Jun 2023 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role: Officer
Signature: /s/ Mark Worthington, Attorney-in-fact for Andrew Gengos
Issuer symbol: ATHA
Transactions as of: 07 Jun 2023
Net transactions value: +$51,445
Form type: 4
Filing time: 09 Jun 2023, 17:06:28 UTC
Previous filing: 06 Jun 2023
Next filing: 08 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATHA	Common Stock	Purchase	$1,417	+422	+0.65%	$3.36	65,434	07 Jun 2023	Direct	F1
transaction	ATHA	Common Stock	Purchase	$9,721	+2,859	+4.4%	$3.40	68,293	07 Jun 2023	Direct
transaction	ATHA	Common Stock	Purchase	$40,308	+11,719	+17%	$3.44	80,012	07 Jun 2023	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $3.355 to $3.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
F2	The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $3.43 to $3.44, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Content

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $3.355 to $3.36, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares purchased. These shares were purchased in multiple transactions at prices ranging from $3.43 to $3.44, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

Remarks:

Chief Financial Officer and Chief Business Officer